In addition, PAK4 lies downstream of EGFR in the ERBB signaling pathway; hence, the nine FDA-approved cancer drugs targeting EGFR should be assessed to see if they ameliorate the effects of PAK4 mutations and could be used to treat HGSOC patients. Here, EGFR is linked to cancer.